iSpecimen Inc. (ISPC)
Company Description
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide.
Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.
The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.
It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions.
The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Country | United States |
IPO Date | Jun 17, 2021 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 53 |
CEO | Robert Bradley Lim |
Contact Details
Address: 450 Bedford Street Lexington, Massachusetts United States | |
Website | https://ispecimen.com |
Stock Details
Ticker Symbol | ISPC |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001558569 |
CUSIP Number | 45032V108 |
ISIN Number | US45032V1089 |
Employer ID | 27-0480143 |
SIC Code | 8731 |
Key Executives
Name | Position |
---|---|
Robert Bradley Lim | Chief Executive Officer, Treasurer, Secretary & Director |
Yuying Liang | Chief Financial Officer |
Annette Arnold | Vice President of Sales & Business Development |
Carly Lejnieks | Vice President of Marketing |
Katharyn Field | President |
Leslie Hoyt | Senior Vice President of Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2025 | NT 10-K | Filing |
Mar 11, 2025 | 8-K | Current Report |
Feb 28, 2025 | 8-K/A | [Amend] Current Report |
Feb 24, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 30, 2025 | 3 | Filing |
Jan 16, 2025 | 8-K | Current Report |
Dec 30, 2024 | 8-K | Current Report |
Dec 20, 2024 | 8-K | Current Report |
Dec 13, 2024 | 3 | Filing |